PrP turnover in vivo and the time to effect of prion disease therapeutics
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1014263 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Taylor L Corridon und 22 weiteren Autor:innen. Beteiligte Einrichtung: Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Prion Diseases, Brain, Prions. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
PrP lowering is effective against prion disease in animal models and is being tested clinically. Therapies in the current pipeline lower PrP production, leaving pre-existing PrP to be cleared according to its own half-life. We hypothesized that PrP’s half-life may be a rate-limiting factor for the time to effect of PrP-lowering drugs, and one reason why late treatment of prion-infected mice is not as effective as early treatment. Using isotopically labeled diet with targeted mass spectrometry, as well as antisense oligonucleotide treatment followed by timed PrP measurement, we estimate a half-life of 5–6 days for PrP in the brain. PrP turnover is not affected by over- or under-expression. Mouse PrP and human PrP have similar turnover rates measured in wild-type or humanized knock-in mice. CSF PrP appears to mirror brain PrP in real time in rats. PrP in the colon is readily quantifiable and has a half-life just slightly shorter than in brain. An under-expressed pathogenic mutant PrP, corresponding to D178N in humans, exhibits an accelerated turnover rate. Our data may inform the design of both preclinical and clinical studies of PrP-lowering drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
- Weissman Hood Institute, Great Falls, Montana, United States of America.
- Ionis Pharmaceuticals, Carlsbad, California, United States of America.
- Charles River Laboratories, Worcester, Massachusetts, United States of America.
- IQ Proteomics, Framingham, Massachusetts, United States of America.
- Comparative Medicine, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
ORCID-Profile: Eric Vallabh Minikel
Förderung
- NIGMS NIH HHS
- NINDS NIH HHS
- National Institutes of Health
- Prion Alliance
- Ionis Pharmaceuticals
- Gate Bio
Zitieren
APA
Corridon, T. L., O'Moore, J., Seerley, A., Sprague, D. A., Lian, Y., Laversenne, V., Noble, B., Kamath, N. G., Serack, F. E., Shaikh, A. B., Erickson, B., Braun, C., DeSouza-Lenz, K., Howard, M., Chan, N., Jackson, W. S., Reidenbach, A. G., Cabin, D. E., Vallabh, S. M., …, & Minikel, E. V. (2026). PrP turnover in vivo and the time to effect of prion disease therapeutics. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1014263
Vancouver
Corridon TL, O'Moore J, Seerley A, Sprague DA, Lian Y, Laversenne V, et al. PrP turnover in vivo and the time to effect of prion disease therapeutics. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1014263
BibTeX
@article{Corridon2026,
author = {Corridon, Taylor L and O'Moore, Jill and Seerley, Alyssa and Sprague, Daniel A and Lian, Yuan and Laversenne, Vanessa and Noble, Briana and Kamath, Nikita G and Serack, Fiona E and Shaikh, Abdul Basit and Erickson, Brian and Braun, Craig and DeSouza-Lenz, Kendrick and Howard, Michael and Chan, Nathan and Jackson, Walker S and Reidenbach, Andrew G and Cabin, Deborah E and Vallabh, Sonia M and Grindeland Panter, Andrea and Oberbeck, Nina and Zhao, Hien T and Minikel, Eric Vallabh},
title = {PrP turnover in vivo and the time to effect of prion disease therapeutics},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1014263}
}
EUVIMED